RP4010 has been also shown to reduce SOCE by inhibiting ORAI1 and the PI3K/Akt pathway when combined with chemo agents (gemcitabine and nab-paclitaxel) in pancreatic ductal adenocarcinoma cells [137]. This evidence concerns the gene AKT1 and pancreatic ductal adenocarcinoma.